Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F528
- Development stage
- Preclinical
- Lead developer
- Gyre Therapeutics
- Modality
- Small Molecules
01
Overview
F528 is a novel small molecule anti-inflammatory agent under preclinical development for the treatment of chronic obstructive pulmonary disease (COPD). It acts by inhibiting multiple inflammatory cytokines, with the potential to modify disease progression in COPD. The drug is being evaluated as a potential first-line therapy for COPD and may have broader applications in other inflammatory conditions. Development activities are primarily reported in China, and it has not yet reached clinical trial phases[1][3].
Beyond the preview
Go deeper on F528.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F528.